Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Beatriz Ruz Caracuel"'
Autor:
Marta Ibáñez-Navarro, Adrián Fernández, Adela Escudero, Gloria Esteso, Carmen Campos-Silva, Miguel Ángel Navarro-Aguadero, Alejandra Leivas, Beatriz Ruz Caracuel, Carlos Rodríguez-Antolín, Alejandra Ortiz, Alfonso Navarro-Zapata, Carmen Mestre-Durán, Manuel Izquierdo, María Balaguer-Pérez, Cristina Ferreras, Joaquín Martínez-López, Mar Valés-Gómez, Antonio Pérez-Martínez, Lucía Fernández
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionRefractory/relapsed pediatric acute leukemia are still clinically challenging and new therapeutic strategies are needed. Interactions between Natural Killer Group 2D (NKG2D) receptor, expressed in cytotoxic immune cells, and its ligands (
Externí odkaz:
https://doaj.org/article/a050597990ec4b1fb78353f27eb60db9
Autor:
Isabel Martínez-Romera, Víctor Galán-Gómez, Berta González-Martínez, Pilar Guerra García, Sonsoles San Román Pacheco, Dolores Corral Sánchez, Yasmina Mozo del Castillo, David Bueno Sánchez, Luisa Sisinni, Alba González Guerrero, Serafin Castellano Dámaso, Elena Sánchez Zapardiel, Beatriz Ruz Caracuel, Antonio Balas Pérez, Antonio Pérez-Martínez
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Treatment targeting CD19 by a chimeric antigen receptor expressed on T cells (anti-CD19 CAR-T) has led to a breakthrough in the management and treatment of relapsed and refractory B- cell acute lymphoblastic leukemia (B-ALL). After infusion, the effi
Externí odkaz:
https://doaj.org/article/ce2688322ec946c8a6d1777dae270900
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Ybarra, Antonio Pérez-Martínez, David Bueno, Leopoldo Martinez, M Martínez, Beatriz Ruz-Caracuel, M D Elorza, P. Rubio, Adela Escudero, J J Pozo-Kreilinger, E Antolín, F Omeñaca, Antonio Pellicer, R M Regojo
Publikováno v:
Clinical and Translational Oncology. 23:1179-1184
Background Neonatal tumors represent an extremely rare and heterogeneous disease with an unknown etiology. Due to its early onset, it has been proposed that genetic factors could play a critical role; however, germline genetic analysis is not usually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf8268feb1e3e3b1e718e6ab5d31f1fd
https://doi.org/10.1007/s12094-020-02508-2
https://doi.org/10.1007/s12094-020-02508-2
Autor:
Cristina Ferreras Bárbara Pascual, Yasmina Mozo, Blanca Rosich, Adela Escudero, Luisa Sisinni, María Isabel Benítez-Carabante, Juan Torres, Carmen Mestre-Duran, Alba Fernández-Arroyo, Laura C. Alonso, David Bueno, Cristina Díaz de Heredia, Beatriz Ruz-Caracuel, María Luz Uría, Itsaso Losantos, Antonio Pérez Martínez
Publikováno v:
Pediatric hematology and oncology. 38(4)
Ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, is a promising treatment for the steroid-refractory graft-vs-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). Most studies have been performed in the adult population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc6683f3d507e7ed7257cd0ab144a49
https://pubmed.ncbi.nlm.nih.gov/33661711
https://pubmed.ncbi.nlm.nih.gov/33661711
Autor:
Lucía Fernández, Alfonso Navarro-Zapata, Cristina Ferreras, Diego Lanzarot, Alicia Pernas, Carlos Rodriguez-Antolin, Alejandra Leivas, Marta Cobo, Aurora Viejo, Joaquín Martínez, Gema Casado, Beatriz Ruz-Caracuel, Carmen Mestre, María Vela, Adela Escudero, Isabel Mirones, Nerea Matamala, Adrián Fernández, Antonio Pérez-Martínez
Publikováno v:
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Cancers
Volume 13
Issue 3
Cancers, Vol 13, Iss 577, p 577 (2021)
Universitat Autònoma de Barcelona
instname
Cancers
Volume 13
Issue 3
Cancers, Vol 13, Iss 577, p 577 (2021)
Universitat Autònoma de Barcelona
Natural killer (NK) cells represent promising tools for cancer immunotherapy. We report the optimization of an NK cell activation–expansion process and its validation on clinical‐scale. Methods: RPMI‐1640, stem cell growth medium (SCGM), NK MAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a550745a88bb61d650bdae1559978c
https://doi.org/10.3390/cancers13030577
https://doi.org/10.3390/cancers13030577
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.